Is ADUS a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Addus HomeCare Corporation provides in-home care to elderly (ADUS) rests on Aging demographics and shift to home: The 65-plus population is growing quickly and both payers and families increasingly prefer care delivered at home over institutional settings because it is cheaper and often preferred. Revenue (TTM) is ~$1.44B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. Whether ADUS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Addus HomeCare Corporation provides in-home care to elderly, chronically ill, and disabled people through three segments: personal care (help with bathing, dressing, meals, and daily activities), hospice (end-of-life care), and home health (skilled nursing and therapy). Personal care is by far the largest piece at roughly 77% of revenue and is funded predominantly by state Medicaid programs, while hospice and home health are largely Medicare-funded. The company operates across many states with heavy concentration in markets like Illinois, New Mexico, and Texas, and has grown for years through a steady stream of acquisitions, most recently a large personal care deal that lifted 2025 revenue sharply. The investment picture is one of defensive, demographically supported growth rather than rapid expansion. Revenue and earnings compound at mid-to-high single digits organically, supplemented by M&A, and margins are thin but stable because the business is labor-intensive and reimbursement-rate driven. The stock tends to react most to Medicaid and Medicare rate decisions, caregiver labor availability, and acquisition cadence, so the core question for an owner is confidence in the durability of government-funded home care as the population ages.
What's the case for buying ADUS?
1. Aging demographics and shift to home
The 65-plus population is growing quickly and both payers and families increasingly prefer care delivered at home over institutional settings because it is cheaper and often preferred. This structural tailwind supports steady demand for Addus's personal care, hospice, and home health services over many years.
2. Personal care volume and rate growth
Personal care, roughly 77% of revenue, is growing on both higher billable hours and rising reimbursement per hour. Management has pointed to state rate support in markets like Texas, Illinois, and New Mexico plus a caregiver app that lifts hours per consumer, targeting mid-single-digit same-store growth.
3. Acquisition-led expansion
Addus has a long track record of buying regional home-care and hospice agencies and integrating them, and a recent large personal care acquisition drove 2025 revenue up more than 20%. A solid cash position and manageable debt give it room to keep consolidating a fragmented market.
4. Hospice and Medicare rate updates
The hospice segment benefits from annual Medicare rate updates and growth in average daily census, and management has framed long-term same-store hospice growth in the upper single digits. Diversifying across personal care, hospice, and home health reduces reliance on any single payer stream.
What are the risks to ADUS?
The largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. Proposed Medicaid or Medicare funding changes at the federal level are a recurring overhang. The business is labor-intensive, so caregiver wage inflation, turnover, and staffing shortages can squeeze already thin margins. Integration risk and the use of debt for acquisitions add execution and balance-sheet sensitivity. Finally, regulatory and compliance exposure across many states and government payers means audits, documentation requirements, and policy shifts are an ongoing part of the model.
How is ADUS valued? (as of July 2026)
Snapshot for ADUS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.44B
- FY2025 revenue: ~$1.42B (up ~23%)
- Q1 2026 revenue: ~$363.6M (up ~7.7%)
- Q1 2026 adjusted EPS: ~$1.62 (up ~14%)
- Market cap: ~$2.1B
- Trailing P/E: ~21x
Addus trades at a low-20s trailing earnings multiple, reflecting a steady, profitable services operator rather than a high-growth name. First quarter 2026 revenue of roughly $363.6 million missed some estimates while adjusted EPS beat, and net income rose about 18% year over year. The 2025 revenue jump was driven mostly by a large personal care acquisition, so underlying organic growth runs closer to mid-single digits.
How do you decide if ADUS is a buy?
Rather than asking whether ADUS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ADUS indirectly through an index or sector ETF before adding more.
For the full picture, see the ADUS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ADUS against your real portfolio and see your actual exposure before deciding.
The bottom line on ADUS
The bottom line: Addus HomeCare Corporation provides in-home care to elderly's story right now is Aging demographics and shift to home, with revenue (ttm) at ~$1.44B. If you believe that narrative continues, the call is about sizing ADUS sensibly and checking overlap with what you own; if you doubt it (the risk: the largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on ADUS
- ADUS stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- ADUS stock forecast (the drivers and risks shaping the outlook)
- Does ADUS pay a dividend?
Build a basket around ADUS with Walnut
Use Addus HomeCare Corporation provides in-home care to elderly as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ADUS a good stock to buy right now?
+
The case for Addus HomeCare Corporation provides in-home care to elderly right now is Aging demographics and shift to home, with revenue (ttm) at ~$1.44B. If you believe that thesis holds, ADUS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Addus HomeCare Corporation provides in-home care to elderly do?
+
Addus HomeCare Corporation provides in-home care to elderly, chronically ill, and disabled people through three segments: personal care (help with bathing, dressing, meals, and dai
What are the main risks of ADUS?
+
The largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. Proposed Medicaid or Medicare funding changes at the federal level are a recurring overhang. The business is labor-intensive, so caregiver wage inflation, turnover, and staffing shortages can squeeze already thin margins. Integration risk and the use of debt for acquisitions add execution and balance-sheet sensitivity. Finally, regulatory and compliance exposure across many states and government payers means audits, documentation requirements, and policy shifts are an ongoing part of the model.
What does Addus HomeCare do?
+
Addus provides in-home care through three segments: personal care (help with daily living activities), hospice (end-of-life care), and home health (skilled nursing and therapy). Personal care is the largest at roughly 77% of revenue and is funded mainly by state Medicaid programs.
How does Addus make money?
+
It bills government and managed-care payers for hours of care and days of service delivered by its caregivers and clinicians. Personal care revenue is driven by billable hours and reimbursement rates, while hospice is paid on a per-day census basis and home health on episodes of care.
Is Addus HomeCare profitable?
+
Yes. It is consistently profitable with net income growing year over year, though margins are thin because the business is labor-intensive and reimbursement-rate driven. First quarter 2026 net income rose about 18% to roughly $25 million.
What are the biggest risks for ADUS?
+
Reimbursement concentration is the main risk: personal care depends on state Medicaid budgets and hospice and home health on Medicare, so rate cuts or funding changes hit revenue directly. Caregiver wage inflation, staffing shortages, and acquisition integration add further risk.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ADUS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.